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Transforming Growth Factor-Beta Induces Senescence
in Hepatocellular Carcinoma Cells and Inhibits
Tumor Growth
Serif Senturk,1 Mine Mumcuoglu,1 Ozge Gursoy-Yuzugullu,1,2 Burcu Cingoz,1
Kamil Can Akcali,1 and Mehmet Ozturk1,2
Senescence induction could be used as an effective treatment for hepatocellular carcinoma
(HCC). However, major senescence inducers (p53 and p16Ink4a) are frequently inactivated in
these cancers. We tested whether transforming growth factor-b (TGF-b) could serve as a poten-
tial senescence inducer in HCC. First, we screened for HCC cell lines with intact TGF-b signal-
ing that leads to small mothers against decapentaplegic (Smad)-targeted gene activation. Five
cell lines met this condition, and all of them displayed a strong senescence response to TGF-b1
(1-5 ng/mL) treatment. Upon treatment, c-myc was down-regulated, p21Cip1 and p15Ink4b
were up-regulated, and cells were arrested at G1. The expression of p16
Ink4a was not induced,
and the senescence response was independent of p53 status. A short exposure of less than 1 mi-
nute was sufﬁcient for a robust senescence response. Forced expression of p21Cip1 and p15Ink4b
recapitulated TGF-b1 effects. Senescence response was associated with reduced nicotinamide
adenine dinucleotide phosphate oxidase 4 (Nox4) induction and intracellular reactive oxygen
species (ROS) accumulation. The treatment of cells with the ROS scavenger N-acetyl-L-cyste-
ine, or silencing of the NOX4 gene, rescued p21Cip1 and p15Ink4b accumulation as well as the
growth arrest in response to TGF-b. Human HCC tumors raised in immunodeﬁcient mice
also displayed TGF-b1–induced senescence. More importantly, peritumoral injection of TGF-
b1 (2 ng) at 4-day intervals reduced tumor growth by more than 75%. In contrast, the dele-
tion of TGF-b receptor 2 abolished in vitro senescence response and greatly accelerated in vivo
tumor growth. Conclusion: TGF-b induces p53-independent and p16Ink4a-independent, but
Nox4-dependent, p21Cip1-dependent, p15Ink4b-dependent, and ROS-dependent senescence
arrest in well-differentiated HCC cells. Moreover, TGF-b–induced senescence in vivo is associ-
ated with a strong antitumor response against HCC. (HEPATOLOGY 2010;52:966-974)
C
ellular senescence is a permanent withdrawal
from the cell cycle in response to diverse stress
conditions such as dysfunctional telomeres,
DNA damage, strong mitotic signals, and disrupted
chromatin. Senescence is considered to be a major
cause of aging, but also a strong anticancer mecha-
nism.1 The relevance of senescence in chronic liver dis-
eases is poorly known, but it may play a central role.
Hepatocyte telomeres undergo shortening during
chronic liver disease progression,2 and this is accompa-
nied by a progressive decline of hepatocyte prolifera-
tion.3 Senescence-associated b-galactosidase (SA-b-
Gal)-positive cells have been detected in 3%-7% of
normal liver, 50% of chronic hepatitis, 70%-100% of
cirrhosis, and up to 60% of hepatocellular carcinoma
(HCC) tissues.2,4-7 Highly abundant senescence
observed in cirrhosis has been conﬁned to hepatocytes2
and stellate cells.8 Because telomere-deﬁcient mice
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develop cirrhosis,9 and cirrhotic hepatocytes display
shortened telomeres, telomere dysfunction was pro-
posed to cause senescence in cirrhosis.2 It is assumed
that HCC tumor cells bypass hepatocellular senescence
to become immortalized. Frequent inactivation of
TP53 (encoding the tumor protein p53) and
CDKN2A (cyclin-dependent kinase inhibitor 2A,
encoding p16Ink4a protein) genes in these tumors sup-
ports this hypothesis.10 Nevertheless, the detection of
senescent cells in some HCC tumors suggests that
transformed and presumably immortal hepatocytes
have maintained the capacity to undergo senescence
arrest under appropriate conditions.
With this regard, immortal HCC cell lines can sponta-
neously generate progeny that undergo replicative senes-
cence11; murine HCC tumors generated by the expres-
sion of a mutant Ras gene in p53-deﬁcient hepatoblasts
can be cleared by a massive senescence response upon
reactivation of p53 expression12; c-myc oncogene inactiva-
tion in murine HCCs results in senescence-mediated tu-
mor regression.13 One of our goals is to identify novel
mechanisms of senescence induction in HCC cells. Here,
we identify the transforming growth factor-beta (TGF-b)
as a major cytokine that is able to trigger a massive senes-
cence response in well-differentiated HCC cell lines.
Reduced nicotinamide adenine dinucleotide phosphate
oxidase-4 (Nox4) and reactive oxygen species (ROS) were
key intermediates of TGF-b–induced growth arrest that
was mediated by p21Cip1 and p15Ink4b.
Materials and Methods
Detailed materials and methods are described in the
Supporting Information Materials and Methods. Cell
lines were tested under standard culture conditions in
the presence of 10% fetal bovine serum. Total RNA
was isolated using a NucleoSpin RNA II Kit
(Macherey-Nagel, Duren, Germany), and ﬁrst-strand
complementary DNA (cDNA) was synthesized using
RevertAid First Strand cDNA synthesis kit (MBI Fer-
mentas, Leon-Rot, Germany). Genomic DNA was
extracted as described,11 and polymerase chain reaction
(PCR) assays were done using appropriate primers.
Quantitative PCR was performed using SYBR Green I
(Invitrogen, Carlsbad, CA). Glyceraldehyde 3-phos-
phate dehydrogenase and b-actin were used as internal
controls. The SA-b-Gal assay was performed as
described.11 Commercial and homemade antibodies
were used. Western blot assays were performed as
described,11 using a-tubulin or calnexin as internal
controls. For immunoperoxidase and immunoﬂuores-
cence assays, cells were ﬁxed with 4% formaldehyde,
permeabilized with phosphate-buffered saline supple-
mented with 0.5% saponin and 0.3% TritonX-100
(Sigma, St. Louis, MO), and subjected to indirect im-
munoﬂuorescence and immunoperoxidase assays. To
test permanent cell cycle arrest, cells were labeled with
bromodeoxyuridine (BrdU) for 24 hours in freshly
added culture media, and the anti-BrdU immunoﬂuo-
rescence assay was performed as described.11 Human
p15Ink4b and p21Cip1 were cloned into pcDNA3.1C/
Neo and pcDNA3.1(þ)/hygromycin (Invitrogen),
respectively. Cells were transfected with Lipofectamine
2000 (Invitrogen) and selected with either Geneticin
G418 (Gibco) or hygromycin-B (Roche, Indianapolis,
IN) for 8 days. The NOX4 gene was silenced using
previously described Nox4-speciﬁc small interfering
RNAs (siRNAs).14 A negative control siRNA was used
in parallel experiments. The siRNAs were transfected
with Lipofectamine RNAiMAX (Invitrogen). The
pSBE4-luc reporter was cotransfected with pRL-TK
(plasmid Renilla luciferase, with thymidine kinase pro-
moter; Promega, Madison, WI), using Lipofectamine
2000. The luciferase assay was performed using a
Dual-Glo luciferase kit (Promega). For cell cycle stud-
ies, ﬁxed cells were labeled with propidium iodide and
analyzed using FACSCalibur Flow Cytometer (BD
Biosciences, San Jose, CA). Intracellular ROS were
detected with 20,70-dichloroﬂuorescein diacetate
(DCFH-DA; Sigma), using MitoTracker Red (Invitro-
gen) as a counterstain. Apoptosis was tested by Nega-
tive in Apoptosis (NAPO)15 and active caspase-3 anti-
body (Asp-175; Cell Signaling Technology, Danvers,
MA) immunoassays. Subcutaneous human HCC
tumors were obtained in CD1 nude mice using 5 
106 live cells per injection. All animals received care
according to the Guide for the Care and Use of Labo-
ratory Animals. Results were expressed as mean 6 stand-
ard deviation from at least three independent experi-
ments. Data between groups were analyzed by one-tailed
t test. A P value <0.05 was considered statistically sig-
niﬁcant. TGF-b1 expression in liver disease was analyzed
using a publicly available global gene expression data,16
which were normalized using JustRMA tool from the
Bioconductor group.17 A two-sample t test with random
variance model was used with a 0.05 nominal signiﬁ-
cance level of each univariate test.
Results
Differential Expression of TGF-b1 in Normal
Liver, Cirrhosis, and HCC. We ﬁrst analyzed TGF-
b1 expression in normal liver, cirrhosis, and HCC,
using the publicly available clinical data sets.16 TGF-
b1 expression displayed a bell-shaped distribution with
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a sharp increase in cirrhosis (cirrhosis versus normal
liver, P < 0.001), followed by a progressive decrease
in early HCC (early HCC versus cirrhosis, P < 0.02)
and advanced HCCs (Supporting Information Fig. 1).
This expression pattern closely correlated with reported
frequencies of SA-b-Gal activities in normal liver, cir-
rhosis, and HCC.2,4-7
TGF-b Is an Autocrine Cytokine Inducing a
Senescence-Like Response in Well-Differentiated HCC
Cell Lines. We hypothesized that TGF-b signaling can
induce hepatocellular senescence response, because it is
a potent inducer of G1 arrest.
18 To test this hypothesis,
we ﬁrst formed a panel of ‘‘well-differentiated’’ HCC
cell lines that display E-cadherin expression, epithelial-
like morphology, and hepatocyte-like gene expres-
sion.19 Well-differentiated cell lines also share the same
TGF-b early response gene expression patterns with
normal hepatocytes.20 All selected cell lines expressed
all critical components of TGF-b signaling including
TGF-b1, TGF-b receptor 1 (TGFBR1), TGFBR2,
small mothers against decapentaplegic homolog 2
(SMAD2), SMAD3, and SMAD4 (Supporting Informa-
tion Fig. 2A). Hep3B-TR clone displaying homozygous
deletion of TGFBR221 was used as a negative control
(Supporting Information Fig. 2). All cell lines, except
Hep3B-TR displayed intact TGF-b signaling activity
(Fig. 1A), as tested by pSBE4-Luc reporter activity.22
Treatment of cells with TGF-b1 (5 ng/mL) yielded
9-fold to 19-fold induction of pSBE4-Luc reporter activ-
ity in responsive cell lines. The expression of endogenous
plasminogen activator inhibitor-1 (PAI-1), a well-known
TGF-b target gene,23 was also induced (Supporting
Information Fig. 3). TGF-b1–treated cell lines were kept
in culture with medium changes (without TGF-b1)
every 3 days, examined morphologically, and subjected
to SA-b-Gal assay. All cell lines tested, except Hep3B-
TR, displayed growth inhibition associated with ﬂattened
cell morphology and >50% positive SA-b-Gal activity,
as early as 3 days after TGF-b1 treatment (Fig. 1B).
Expression of TGF-b1 in all tested cell lines sug-
gested that it could act as an autocrine cytokine.
Therefore, we exposed Huh7 cells to either anti-TGF-
b1 antibody (5 lg/mL) or TGF-b1 (5 ng/mL) and
tested for total and SA-b-Gal–positive cells in isolated
colonies 10 days later. Cells treated with anti-TGF-b1
antibody displayed two-fold increased colony size (P <
0.04) and 50% decreased SA-b-Gal activity (P < 0.02;
Supporting Information Fig. 4). In contrast, ectopic
TGF-b1 treatment caused a seven-fold decrease in col-
ony size (P < 0.005) and ﬁve-fold increase in SA-b-
Gal activity (P < 0.0001). Thus, Huh7 cells produced
TGF-b1 acting as a weak autocrine senescence-induc-
ing signal that was inhibited by anti-TGF-b1 antibody,
and ampliﬁed by ectopic TGF-b1.
A Brief Exposure to TGF-b for a Robust
Senescence Response. To test the shortest time of ex-
posure to TGF-b1 for a full senescence response, three
cell lines were treated with TGF-b1 for durations
between <1 minute (20 seconds) and 72 hours, and
subjected to SA-b-Gal staining. To our surprise, <1
minute exposure was sufﬁcient for a robust senescence
response (Fig. 2). Thus, the senescence-initiating effect
of TGF-b1 was immediate, even though the senes-
cence phenotype (>50% SA-b-Gal–positive and ﬂat-
tened cells) was manifested 3 days later.
Lack of Evidence for TGF-b–Induced Apoptosi-
s. Earlier studies indicated that TGF-b induces apo-
ptosis in hepatocytes and some HCC cell lines under
serum-free conditions.24-27 Under our experimental
conditions using 10% fetal bovine serum, all ﬁve cell
lines tested failed to enter apoptosis following TGF-b
Fig. 1. Well-differentiated HCC cell lines are competent for TGF-b
signaling activity and they respond to TGF-b by potent senescence-like
growth arrest. (A) Cells were cotransfected with pSBE4-Luc and control
pRL-TK plasmids, and treated with or without TGF-b1 (5 ng/mL) for
24 hours. The luciferase activity was measured and expressed as fold-
activity of pSBE4-Luc/pRL-TK (mean 6 standard deviation; n ¼ 3).
(B) Cells were plated at low density and treated with 1 or 5 ng/mL
TGF-b1, and tested for SA-b-Gal activity (blue) at days 3 and 7.
Counterstain: Fast Red. TGFBR2-deleted Hep3B-TR cells were used as
negative controls in (A) and (B).
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treatment, as examined by NAPO antibody15 and acti-
vated caspase-3–speciﬁc antibody tests (Supporting In-
formation Figs. 5 and 6).
TGF-b–Induced Senescence Is Associated with
Sustained Induction of p21Cip1 and p15Ink4b. Cellu-
lar senescence is usually associated with cell cycle arrest
induced by p53, p21Cip1, p16Ink4a, and/or p15Ink4b.1,28
TGF-b1 caused c-myc repression and p15Ink4b and
p21Cip1 induction (Fig. 3; Supporting Information Fig.
7A). Decreased pRb phosphorylation, together with
decreased p107 and increased p130 protein levels, was
also observed. These changes in retinoblastoma family
proteins correlate with exit from the cell cycle.29 The
TGF-b response was independent of p53. All HCC cell
lines tested here, except HepG2, display p53 muta-
tions.30 The levels of total p53 did not change following
TGF-b exposure, despite p21Cip1 accumulation (Fig.
3; Supporting Information Fig. 7B). Moreover, we
observed no phosphorylation of wild-type p53 in
HepG2 cells, following TGF-b exposure (Supporting In-
formation Fig. 7B). TGF-b also did not affect p16Ink4a
levels (Fig. 3). Indeed, the CDKN2A gene is frequently
silenced in HCC.31 Accordingly, p16Ink4a protein levels
were extremely low in all tested cell lines, except in
pRb-deﬁcient Hep3B and Hep3B-TR cells (Supporting
Information Fig. 7C). On the other hand, our
Fig. 2. Induction of a strong se-
nescence-like response by TGF-b
after a very short exposure. Cells
were treated with TGF-b1 (5 ng/
mL) for the indicated times, and
SA-b-Gal activity (blue) was tested
at 72 hours. Control: no TGF-b1
treatment. Counterstain: Fast Red.
Fig. 3. TGF-b treatment of HCC cell lines
causes the induction of p15Ink4b and p21Cip1
that is associated with c-myc down-regulation,
pRb underphosphorylation, p107 decrease
and p130 increase. The levels of p53 and
p16Ink4a did not change. Untreated and TGF-
b1–treated cells were tested for indicated pro-
teins by western blotting on day 3. ppRb:
phospho-Ser807/Ser811-pRb, upRb: under-
phosphorylated pRb. The a-tubulin served as
an internal control. p16Ink4a blots were over-
exposed to visualize weak expression.
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observation of senescence arrest in Hep3B cells suggests
that pRb expression is also dispensable for TGF-b–
induced senescence in HCC cells. Taken together, these
ﬁndings suggested that TGF-b was able to induce senes-
cence in HCC cells independent of p53, p16Ink4a, or
pRb status.
TGF-b Induces a Permanent G1 Arrest that Can
Be Reproduced Either by p21Cip1 or p15Ink4b. Cellu-
lar senescence is deﬁned as an irreversible arrest of mitotic
cells at the G1 phase, but some cancer cells enter senescence
at the G2 or S phases.
1 Initially, we used Huh7 cells for cell
cycle studies. These cells accumulated at G1 phase (from
59% to 81%) with a concomitant depletion of S phase
cells (from 18% to 8%), after TGF-b1 exposure (Fig. 4A).
Similar results were obtained with PLC/PRF/5 cells (Fig.
5) and other cell lines (data not shown). These observa-
tions suggested that p21Cip1 and/or p15Ink4b are involved
in TGF-b–mediated G1 arrest and senescence response.
Therefore, we tested respective contributions of p21Cip1
and p15Ink4b in these responses, by transient transfection
assays using Huh7 cells. The p21Cip1-transfected and
p15Ink4b-transfected cells demonstrated highly increased
p21Cip1 protein (Supporting Information Fig. 8A) and
moderately increased p15Ink4b expression (Supporting In-
formation Fig. 8B), respectively. The p21Cip1-overexpress-
ing cells accumulated at G1 (from 61% to 78%), together
with a depletion of S phase cells (from 26% to 13%; Fig.
4B). In association with these changes, SA-b-Gal activity
was increased (Supporting Information Fig. 9A) and BrdU
Fig. 4. G1 arrest induced by TGF-b treatment can be recapitulated
by ectopic expression of p21Cip1 and p15Ink4b. (A) Control and TGF-
b1–treated Huh7 cells were subjected to cell cycle analysis after 3
days of culture. (B, C) Huh7 cells were transiently transfected with (B)
p21Cip1 and (C) p15Ink4b expression vectors, and subjected to cell
cycle analysis after 8 days of culture. Control: cells transfected with
empty plasmid vectors (B,C). [Color ﬁgure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
Fig. 5. Implication of Nox4 induction and ROS accumulation in TGF-
b–induced growth arrest. (A) TGF-b1 treatement induces the expression
of Nox4, p15Ink4b, and p21Cip1 together with ppRb down-regulation; ROS
scavenger NAC inhibits p15Ink4b and p21Cip1 induction, and ppRb down-
regulation, but not Nox4 accumulation. Cell lysates were collected at day
3, following treatment with TGF-b1 and/or NAC, and tested by western
blotting. (B-D) ROS accumulation observed in TGF-b1–treated cells is
inhibited by NAC cotreatment (B), and this results in (C) inhibition of G1
arrest, and (D) restoration of BrdU incorporation into cellular DNA. (A)
PLC/PRF/5 cells were treated for 3 days with either 10 mM NAC or 5
ng/mL TGF-b1 alone, or in combination, and tested for Nox4, p15Ink4b,
p21Cip1, and ppRb by western blotting. (B) Huh7 and PLC/PRF/5 (PLC)
cells were treated with either 10 mM NAC or 5 ng/mL TGF-b1 alone, or
in combination, and tested for ROS accumulation using a green ﬂuores-
cent ROS indicator, and a red ﬂuorescent mitochondrial marker as coun-
terstain. The effects of 10 mM NAC cotreatment on growth inhibition by
TGF-b1 (0, 1, or 5 ng/mL) were tested by (C) cell cycle analysis, and
(D) BrdU incorporation assay. Blue, red, and green columns in (C) repre-
sent cells at G1, S, and G2/M, respectively.
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incorporation into cellular DNA was inhibited (P <
0.001; Supporting Information Fig. 9B). The p15Ink4b
overexpression caused a moderate response (G1 cells rising
to 66% from 59%; S phase cells decreasing from 22%
from 15%; Fig. 4C). However, p15Ink4b overexpression
was also associated with increased SA-b-Gal activity (Sup-
porting Information Fig. 9C) and decreased BrdU incor-
poration (P < 0.001; Supporting Information Fig. 9D).
TGF-b–Induced Senescence Depends on Nox4
Induction and Intracellular Accumulation of
ROS. TGF-b induces Nox4 expression and ROS accu-
mulation in hepatocytes.32-34 Because ROS have been
implicated in Ras-induced senescence,35 we tested whether
TGF-b–induced senescence was associated with Nox4
induction and ROS accumulation. TGF-b1 induced Nox4
protein expression (Fig. 5A; Supporting Information Fig.
10A), as well as ROS accumulation (Fig. 5B). First, we
used N-acetyl-L-cysteine (NAC) as a physiological ROS
scavenger36 to test the role of ROS in TGF-b–induced se-
nescence. The cotreatment of 5 ng/mL TGF-b1–treated
cells with 10 mM NAC completely suppressed the accu-
mulation of ROS (Fig. 5B) and TGF-b1 effects on
p15Ink4b, p21Cip1, and pRb, but not Nox4 expression (Fig.
5A). More importantly, NAC cotreatment rescued cells
from TGF-b1–induced senescence response (Supporting
Information Fig. 10B) and growth arrest (Fig. 5C,D; Sup-
porting Information Fig. 11). Next, we silenced NOX4
gene in Huh7 cells using a previously described NOX4-
speciﬁc siRNA.14 NOX4-speciﬁc siRNA inhibited the
accumulation of Nox4 transcripts (75%; Fig. 6A) and
protein (Fig. 6B) under TGF-b1 treatment. This resulted
in a strong inhibition of p21Cip1 accumulation and a mod-
erate inhibition of p15Ink4b accumulation in association
with restoration of pRb phosphorylation (Fig. 6B). More
importantly, Nox4 inhibition was sufﬁcient to restore cell
proliferation under TGF-b treatment (Fig. 6C).
TGF-b–Induced Senescence and Antitumor Activity
In Vivo. We tested in vivo relevance of TGF-b–
induced senescence in human HCC tumors raised in
Fig. 6. Rescue of TGF-b–induced p21Cip1 and p15Ink4b accumulation and growth arrest by NOX4 gene silencing. (A) TGF-b–induced accumula-
tion of Nox4 transcripts was strongly inhibited by Nox4 siRNA, but not by control siRNA. Transcript analysis was performed by quantitative reverse
transcription PCR. (B) NOX4 gene silencing rescued TGF-b–induced Nox4, p21Cip1, and p15Ink4b protein accumulation, and the inhibition of pRb
phosphorylation, as tested by western blotting. Compared to others, the inhibition of p15Ink4b accumulation was modest. (C) NOX4 gene silenc-
ing also rescued TGF-b–induced inhibition of DNA synthesis, as tested by BrdU incorporation. Cells were labeled with BrdU for 24 hours prior to
day 3, and percent BrdU-positive cells were counted manually.
Fig. 7. TGF-b induces senescence and inhibits the growth of Huh7
tumors in nude mice. (A,B) TGF-b1–induced SA-b-Gal activity in Huh7
tumors. Huh7 tumors were obtained in nude mice and treated with TGF-b1
(0.5 ng) or a vehicle only. (A) Animals were sacriﬁced 7 days later to col-
lect tumor tissues. (B) Cryostat sections from freshly frozen tumors were
subjected to SA-b-Gal staining (blue). Counterstain: Fast Red. (C) Huh7
tumors were treated with 2 ng TGF-b or vehicle only at 4-day intervals and
tumor sizes were measured. TGF-b–treated tumors were growth arrested,
resulting in >75% inhibition of tumor growth. *P < 0.05; **P < 0.01.
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immunodeﬁcient mice. TGF-b1 (50 lL of a 10 ng/
mL solution)-injected Huh7 tumors were removed 1
week later (Fig. 7A) and subjected to SA-b-Gal stain-
ing. TGF-b1 induced local but expanded SA-b-Gal ac-
tivity in three of four tumors tested; three tumors
treated with vehicle only were negative (Fig. 7B).
To test antitumor effects of TGF-b, early Huh7
tumors were treated with peritumoral injection of 2
ng TGF-b at 4 days of intervals. Vehicle-treated tumors
displayed exponential growth to reach 4 cm3 volume on
average within 24 days. In contrast, TGF-b–treated
tumors were growth arrested throughout the experiment
and remained <1 cm3 on average at the same time pe-
riod. Tumor inhibition was signiﬁcant for at least 24
days (P < 0.01 to P < 0.05). The TGF-b treatment was
stopped at day 24 and animals were observed for an
additional period of 4 weeks. All vehicle-treated and
four TGF-b–treated animals died, whereas complete
remission was observed in two TGF-b–treated animals
(data not shown). We also compared TGFBR2-deleted
Hep3B-TR cells21 with parental Hep3B cells. Hep3B-
TR cells formed palpable tumors 2 weeks after subcuta-
neous injection, and host animals died within 4-6
weeks. In contrast, Hep3B cells formed tumors with a
latency of 6-7 weeks (Supporting Information Fig. 12).
Discussion
Our ﬁndings provide strong evidence for senescence
as a major response of HCC cells to TGF-b. Senes-
cence-associated changes included ﬂattened morphol-
ogy, p21Cip1 and p15Ink4b accumulation, and positive
SA-b-Gal activity. This response has not been noticed
previously, probably because of its late occurrence, at
least 3 days after TGF-b treatment. The primary ﬁnd-
ings of our mechanistic studies on TGF-b–induced se-
nescence in HCC cells are outlined in Fig. 8. TGF-b-
induced senescence response was associated with
p21Cip1-mediated and p15Ink4b-mediated G1 arrest, in-
dependent of p53 or p16Ink4a. This correlates with the
earlier observations showing that TGF-b uses p21Cip1
and p15Ink4b, but not p16Ink4a nor p53 to induce G1
arrest in other cell types.18 Although TGF-b–induced
senescence had been described many years ago,37 its
mechanisms are poorly understood. Here, we show
that the overexpression of p21Cip1, and p15Ink4b to a
lesser degree, recapitulates TGF-b–induced senescence
response. Thus, p21Cip1 and p15Ink4b are able to
induce G1 arrest and senescence response in HCC
cells, as it occurs in other cell types.10 Our most inter-
esting ﬁnding was the implication of both Nox4 and
ROS in the induction of p21Cip1 and p15Ink4b, and
G1 arrest by TGF-b. Either NOX4 gene silencing or
ROS scavenging was sufﬁcient to interrupt the TGF-b
signaling toward growth arrest mediated by p21Cip1
and p15Ink4b induction. Thus, the accumulation of
both Nox4 protein and ROS is a critical step for
p21Cip1 and p15Ink4b accumulation in TGF-b–exposed
HCC cells (Fig. 8). Inhibition of p21Cip1-mediated
ROS accumulation has been previously shown to res-
cue senescence,38 and a feedback between p21Cip1 and
ROS production was necessary for stable growth
arrest.39
Our ﬁndings also provided preliminary evidence for
antitumor activity of TGF-b against HCC. This effect
was associated with in vivo induction of SA-b-Gal ac-
tivity in tumor cells. Thus,TGF-b–induced senescence
in human HCC cells, similar to p53-induced senes-
cence in mouse HCC cells,12 may be a potent tumor
suppressor mechanism. The accelerated tumorigenesis
of TGFBR2-deleted Hep3B-TR cells supports this hy-
pothesis. Previous studies indicated that the disruption
of TGF-b signaling in mice through dominant-nega-
tive Tgfr2 (transforming growth factor receptor 2)
accelerates chemically induced hepatocarcinogenesis.40
A similar disruption in b-spectrin embryonic liver
fodrin knockout mice also leads to hepatocellular can-
cer.41,42 However, our ﬁndings are limited to well-dif-
ferentiated HCC cells that represent early forms of
HCC.43 Poorly differentiated HCC cell lines appear to
Fig. 8. A hypothetical model summarizing major components of
TGF-b–induced senescence in HCC cells.
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be resistant to TGF-b-induced senescence (S. Senturk
and M. Ozturk, unpublished data). Nevertheless,
TGF-b treatment might be an attractive therapeutic
option for early HCCs.
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